In HER2 + breast cancer, patients with elevated tsMHC-II expression exhibited enhanced CD8 + and CD4 + T cell infiltration and reduced T cell-to-tumor distances (Fig. 5G and 5H), patterns paralleled in tsMHC-I-high tumors (Fig. S4F). Here, ERBB2 is linked to breast cancer.